Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma

British Journal of Clinical Pharmacology

Volumn 83, Issue 4, 2017, Pages 846-854

  Agarwal, Suresh K ^a   Salem, Ahmed Hamed ^a,b   Danilov, Alexey V ^c,d   Hu, Beibei ^a   Puvvada, Soham ^e   Gutierrez, Martin ^f   Chien, David ^a   Lewis, Lionel D ^c   Wong, Shekman L ^a  

^a ABBVIE INC   (United States)

^b African Union Organization St Abbassia   (Egypt)

^c NORRIS COTTON CANCER CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BCL 2; drug drug interaction; ketoconazole; pharmacokinetics; venetoclax

Indexed keywords

CREATININE; KETOCONAZOLE; VENETOCLAX; ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A INHIBITOR; FUSED HETEROCYCLIC RINGS; PROTEIN BCL 2; SULFONAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FEMALE; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOKALEMIA; MALE; NONHODGKIN LYMPHOMA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; URETER OBSTRUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG INTERACTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG INTERACTIONS; FEMALE; HUMANS; KETOCONAZOLE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 85010223498     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13175     Document Type: Article

References (27)

1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 2016; 44: D1054–68.
2. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al. The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 2015; 172: 5729–5743.
3. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al. The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 2015; 172: 6110–6202.
4. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 2015; 172: 6024–6109.
5. Akl H, Vervloessem T, Kiviluoto S, Bittremieux M, Parys JB, De Smedt H, et al. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum. Biochim Biophys Acta 1843; 2014: 2240–2252.
6. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374: 311–322.
7. Ma S, Brander DM, Seymour JF, Kipps TJ, Barrientos JC, Davids MS, et al. Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study [abstract]. Blood 2015; 126: 830.
8. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukaemia. Cancer Discov 2016; 6: 1106–1117.
9. Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Safety and efficacy of venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma: phase 1b results [abstract]. Blood 2015; 126: 3038.
10. De Vos S, Swinnen L, Kozloff M, Wang D, Reid E, Nastoupil L, et al. A dose-escalation study of venetoclax (ABT-199/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin's lymphoma [abstract]. Blood 2015; 126: 255.
11. DiNardo C, Pollyea D, Pratz K, Thirman MJ, Letai A, Frattini M, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥65 years and not eligible for standard induction therapy [abstract]. Blood 2015; 126: 327.
12. Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol 2016; 56: 1335–1343.
13. Salem AH, Agarwal S, Dunbar M, Nuthalapati S, Chien D, Freise KJ, et al. Effect of low and high fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor. J Clin Pharmacol 2016; 56: 1355–1361.
14. Jones AK, Freise KJ, Agarwal S, Humerickhouse RA, Wong SL, Salem AH. Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin's lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J 2016; 18: 1192–1202.
15. Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J, et al. Absorption, Metabolism, and Excretion of a Novel Bcl-2 Inhibitor Venetoclax in Humans. Drug Metab Dispos 2016. doi:10.1124/dmd.116.071613.
16. Choo EF, Boggs J, Zhu C, Lubach JW, Catron ND, Jenkins G, et al. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199. Drug Metab Dispos 2014; 42: 207–212.
17. US Department of Health and Human Services. Guidance for Industry: Drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); February 2012, pp. 39–40.
18. Kikuchi R, Shebley M, Bow AJ, Carr RA, Nijsen M, de Morais SM. In vitro characterization of drug metabolizing enzymes and transporters to enable a mechanistic drug–drug interaction assessment for venetoclax [abstract P86]. International Society for the Study of Xenobiotics; June 2016, Busan, Korea.
19. Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL. Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. Clin Drug Investig 2016. doi:10.1007/s40261-016-0485-9.
20. Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, et al. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. J Clin Pharmacol 2009; 49: 398–406.
21. Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, et al. Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Pharmacokinet 2016. doi:10.1007/s40262-016-0453-9.
22. Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, et al. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy, Hematological Oncology 2016. doi:10.1002/hon.2373.
23. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda W, et al. A phase 1 first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 2016; In press.
24. Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin's lymphoma. J Clin Pharmacol 2016. doi:10.1002/jcph.821.
25. Freise KJ, Dunbar M, Jones AK, Hoffman D, Enschede SL, Wong S, et al. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. Cancer Chemother Pharmacol 2016; 78: 847–853.
26. Freise KJ, Shebley M, Salem AH. Quantitative prediction of the effect of CYP3A inhibitors and inducers on venetoclax pharmacokinetics using a physiologically-based pharmacokinetic model. J Clin Pharmacol 2016. doi:10.1002/jcph.858.
27. Salem AH, Yang J, Graham A, Patnaik A, Holen K, Pradhan R, et al. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients. Anticancer Res 2014; 34: 2001–2006.